Who Paid My Doc
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Eff
Research payments
$7,851,881
Through program year 2025, $7,851,881 in research payments was reported against A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Eff, across 895 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $39,332 | 14 |
| 2024 | Research | $574,899 | 142 |
| 2023 | Research | $403,132 | 135 |
| 2022 | Research | $1,178,847 | 289 |
| 2021 | Research | $1,721,682 | 126 |
| 2020 | Research | $3,933,989 | 189 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Gail Wright Trinity, FL Named on 72 payments
- Kristopher Lybarger Kansas City, MO Named on 43 payments
- Timothy Vanderkwaak Sylva, NC Named on 24 payments
- Gottfried Konecny Los Angeles, CA Named on 24 payments
- Robert Morris Detroit, MI Named on 21 payments
- Eirwen Miller Pittsburgh, PA Named on 21 payments
- Fadi Kayali Sarasota, FL Named on 20 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.